Sumiko Hamamoto
Kawasaki Medical School
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sumiko Hamamoto.
American Journal of Physiology-endocrinology and Metabolism | 2010
Yukiko Kanda; Masashi Shimoda; Sumiko Hamamoto; Kazuhito Tawaramoto; Fumiko Kawasaki; Mitsuru Hashiramoto; Koji Nakashima; Michihiro Matsuki; Kohei Kaku
Pioglitazone preserves pancreatic β-cell morphology and function in diabetic animal models. In this study, we investigated the molecular mechanisms by which pioglitazone protects β-cells in diabetic db/db mice. In addition to the morphological analysis of the islets, gene expression profiles of the pancreatic islet were analyzed using laser capture microdissection and were compared with real-time RT-PCR of db/db and nondiabetic m/m mice treated with or without pioglitazone for 2 wk or 2 days. Pioglitazone treatment (2 wk) ameliorated dysmetabolism, increased islet insulin content, restored glucose-stimulated insulin secretion, and preserved β-cell mass in db/db mice but had no significant effects in m/m mice. Pioglitazone upregulated genes that promote cell differentiation/proliferation in diabetic and nondiabetic mice. In db/db mice, pioglitazone downregulated the apoptosis-promoting caspase-activated DNase gene and upregulated anti-apoptosis-related genes. The above-mentioned effects of pioglitazone treatment were also observed after 2 days of treatment. By contrast, the oxidative stress-promoting NADPH oxidase gene was downregulated, and antioxidative stress-related genes were upregulated, in db/db mice treated with pioglitazone for 2 wk, rather than 2 days. Morphometric results for proliferative cell number antigen and 4-hydroxy-2-noneal modified protein were consistent with the results of gene expression analysis. The present results strongly suggest that pioglitazone preserves β-cell mass in diabetic mice mostly by two ways; directly, by acceleration of cell differentiation/proliferation and suppression of apoptosis (acute effect); and indirectly, by deceleration of oxidative stress because of amelioration of the underlying metabolic disorder (chronic effect).
Diabetes, Obesity and Metabolism | 2013
Sumiko Hamamoto; Yukiko Kanda; Masashi Shimoda; Fuminori Tatsumi; Kenji Kohara; Kazuhito Tawaramoto; Mitsuru Hashiramoto; Kohei Kaku
We investigated the molecular mechanisms by which vildagliptin preserved pancreatic β cell mass and function.
Molecular and Cellular Endocrinology | 2015
Tomohiko Kimura; Hideaki Kaneto; Masashi Shimoda; Hidenori Hirukawa; Seizo Okauchi; Kenji Kohara; Sumiko Hamamoto; Kazuhito Tawaramoto; Mitsuru Hashiramoto; Kohei Kaku
The aim was to compare the protective effects of pioglitazone (PIO) and/or liraglutide (LIRA) on β-cells with the progression of diabetes. Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage. In an early stage insulin biosynthesis and secretion were markedly increased by PIO and LIRA which was not observed in an advanced stage. In concomitant with such phenomena, expression levels of various β-cell-related factors were up-regulated by PIO and LIRA only in an early stage. Furthermore, β-cell mass was also increased by the treatment only in an early stage. Although there was no difference in apoptosis ratio between the two stages, β-cell proliferation was augmented by the treatment only in an early stage. In conclusion, protective effects of pioglitazone and/or liraglutide on β-cells were more powerful in an early stage of diabetes compared to an advanced stage.
Diabetes & Metabolism | 2015
Sumiko Hamamoto; Hideaki Kaneto; Shinji Kamei; Masashi Shimoda; Kazuhito Tawaramoto; Yukiko Kanda-Kimura; Fumiko Kawasaki; Mitsuru Hashiramoto; Michihiro Matsuki; Tomoatsu Mune; Kohei Kaku
Diabetes & Metabolism - In Press.Proof corrected by the author Available online since lundi 8 juin 2015
Diabetes Care | 2016
Kenji Kohara; Hideaki Kaneto; Shinji Kamei; Masashi Shimoda; Sumiko Hamamoto; Kazuhito Tawaramoto; Michihiro Matsuki; Tomoatsu Mune; Kohei Kaku
A 71-year-old woman with type 2 diabetes was referred to our hospital because of severe lipoatrophy throughout the whole abdomen induced by insulin therapy. The patient was diagnosed with type 2 diabetes when she was 63 years old and was treated with diet therapy only. When she was 69, her glycemic control became poor and insulin therapy was introduced (before breakfast, 20 units biphasic insulin Novolin 30R). Just after treatment began, she noticed that her abdomen gradually became atrophic, but she left it as it was. HbA1c levels were ∼8–9% (64–75 mmol/mol). She was treated only with biphasic insulin, and other antidiabetes agents were not used. Since her understanding about diabetes was poor, it was possible that she forgot to rotate the insulin injection site. When she was 71 years old, her glycemic control became …
Molecular and Cellular Endocrinology | 2012
Koji Nakashima; Masashi Shimoda; Sumiko Hamamoto; Fuminori Tatsumi; Hidenori Hirukawa; Kazuhito Tawaramoto; Yukiko Kanda; Kohei Kaku
Based on the hypothesis that MIN6 cells could produce glucagon-like peptide-1 (GLP-1) to maintain cell survival, we analyzed the effects of GLP-1 receptor agonist, exendin-4 (Ex4), and antagonist, exendin-(9-39) (Ex9) on cell function and cell differentiation. MIN6 cells expressed proglucagon mRNAs and produced GLP-1, which was accelerated by Ex4 and suppressed by Ex9. Moreover, Ex4 further enhanced glucose-stimulated GLP-1 secretion, suggesting autocrine loop-contributed amplification of the GLP-1 signal. Ex4 up-regulated cell differentiation- and cell function-related CREBBP, Pdx-1, Pax6, proglucagon, and PC1/3 gene expressions. The confocal laser scanning images revealed that GLP-1 positive cells were dominant in the early stage of cells, but positive for insulin were more prominent in the mature stage of cells. Ex4 accelerated cell viability, while Ex9 and anti-GLP-1 receptor antibody enhanced cell apoptosis. MIN6 cells possess a mechanism of GLP-1 signal amplification in an autocrine fashion, by which the cells maintained insulin production and cell survival.
Journal of Nutritional Biochemistry | 2015
Yukiko Kanda; Mitsuru Hashiramoto; Masashi Shimoda; Sumiko Hamamoto; Kazuhito Tawaramoto; Tomohiko Kimura; Hidenori Hirukawa; Koji Nakashima; Kohei Kaku
To assess the molecular mechanisms by which dietary restriction preserves the β-cell mass and function in diabetic db/db mice. Male db/db mice were divided into two groups with or without diet restriction. Daily food intake of db/db mice was adjusted to that of the control db/m mice, which was determined in advance. A dietary restriction was implemented for 6 weeks from 6 weeks of age. Islet morphology, β-cell function and gene expression profiles specific for pancreatic islet cells were compared. Food intake in db/m mice was 50% of that in db/db mice. Impaired glucose tolerance and insulin sensitivity were significantly ameliorated in db/db mice with dietary restriction. The pancreatic β-cell mass was greater in mice with dietary restriction than that in mice without intervention. The dietary restriction significantly increased cyclin D gene expression and down-regulated CAD gene expression at 12 weeks compared with untreated db/db mice. Antiapoptotic bcl-2 gene expression was significantly increased, whereas genes related to oxidative stress, ER stress and inflammatory processes, such as NADPH oxidase, CHOP10 and TNF, were markedly down-regulated in mice with dietary restriction. Dietary restriction preserved the pancreatic β-cell function and β-cell mass in diabetic db/db mice, suggesting that alimentary therapy prevented β-cell loss by suppressing cellular apoptosis and antioxidative stress in the pancreatic β cells.
Endocrine Journal | 2015
Fuminori Tatsumi; Hideaki Kaneto; Mitsuru Hashiramoto; Kazuhito Tawaramoto; Atsushi Obata; Tomohiko Kimura; Masashi Shimoda; Sumiko Hamamoto; Yukiko Kanda-Kimura; Shinji Kamei; Tomoatsu Mune; Masafumi Matsuda; Kohei Kaku
It is known that reactive oxygen species (ROS) are involved in the development of insulin resistance as well as pancreatic β-cell dysfunction both of which are often observed in type 2 diabetes. In this study, we evaluated the effects of azelnidipine, a calcium channel blocker, on ROS-mediated insulin resistance in adipocytes. When 3T3-L1 adipocytes were exposed to ROS, insulin-mediated glucose uptake was suppressed, but such phenomena were not observed in the presence of azelnidipine. Phosphorylation of insulin receptor and phosphorylation of Akt were suppressed by ROS, which was mitigated by azelnidipine treatment. Activation of the JNK pathway induced by ROS was also reduced by azelnidipine. Various inflammatory cytokine levels were increased by ROS, which was also suppressed by azelnidipine treatment. In contrast, adiponectin mRNA and secreted adiponectin levels were reduced by ROS, which was refilled by azelnidipine treatment. In conclusion, azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes.
Diabetologia | 2011
Masashi Shimoda; Yukiko Kanda; Sumiko Hamamoto; Kazuhito Tawaramoto; Mitsuru Hashiramoto; Michihiro Matsuki; Kohei Kaku
Molecular and Cellular Endocrinology | 2015
Hidenori Hirukawa; Hideaki Kaneto; Masashi Shimoda; Tomohiko Kimura; Seizo Okauchi; Atsushi Obata; Kenji Kohara; Sumiko Hamamoto; Kazuhito Tawaramoto; Mitsuru Hashiramoto; Kohei Kaku